Egg DonationDONOVO-NancyNCT07468331
Egg Donation at the Assisted Reproductive Technology (ART) Center of the Nancy University Hospital
An observational study of Egg Donation and Infertility Assisted Reproductive Technology, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
Since the 2021 revision of French bioethics laws, access to assisted reproductive technologies (ART) has expanded, leading to a significant increase in gamete donation requests. In this context, oocyte donation remains a limited resource, with marked disparities between centers and persistent donor shortages. Read more about this study
- Who is it for?
- Ages 18 to 38 years, women only
- Conditions the study is for
- Egg Donation, Infertility Assisted Reproductive Technology
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- Mar 2026to May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 38 years
- Women only
- No healthy volunteers
- Adult
Study population: The study population includes all women evaluated for primary or secondary oocyte donation at Nancy University Hospital during the study period. All candidates who attended a biological consultation and initiated the donation assessment process are included, irrespective of donation completion status.
Who may be able to join
- All women who attended a biological consultation for primary or secondary oocyte donation at Nancy University Hospital during the study period.
Who cannot join
- Absence of biological consultation for oocyte donation during the study period ;
- Insufficient or missing medical data ;
- Documented opposition to data use for research purposes.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
University Hospital of Nancy (CHRU Nancy)
Nancy
Caroline AIMONE-VIANNA, +33631785041, c.aimonevianna@chru-nancy.fr
About this study
Official title: DONOVO-Nancy: Egg Donation at the Assisted Reproductive Technology (ART) Center of the Nancy University Hospital: an Overview of the Donor Journey Since the Revisions to the Bioethics Laws
Since the 2021 revision of French bioethics laws, access to assisted reproductive technologies (ART) has expanded, leading to a significant increase in gamete donation requests. In this context, oocyte donation remains a limited resource, with marked disparities between centers and persistent donor shortages.
At the Assisted Reproductive Technology Center of Nancy University Hospital, more than fifty women have initiated an oocyte donation process since the implementation of the new legislation. However, not all candidates complete the donation pathway, and clinical and organizational outcomes have not yet been formally evaluated.
Read more
This retrospective observational study will evaluate the oocyte donation pathway at the Assisted Reproductive Technology Center of Nancy University Hospital. The study population will include all women who attended a biological consultation for primary or secondary oocyte donation from the implementation of the new Bioethics laws until December 31, 2025 (study period).
Baseline clinical and biological characteristics of donor candidates will be described, including age, body mass index, anti-Müllerian hormone level, and antral follicle count.
The proportion of donor candidates undergoing oocyte retrieval and the time interval between the first biological consultation and oocyte retrieval will be assessed.
Biological and clinical outcomes will also be analyzed, including the number of oocytes retrieved, the number of mature oocytes (metaphase II) obtained, fertilization rate following in vitro fertilization, clinical pregnancy rate per embryo transfer, and live birth rate.
Results will be compared with national data reported by the French Biomedicine Agency in order to evaluate the activity and outcomes of the center and to identify potential areas for organizational and clinical improvement in the oocyte donation pathway.
The overall objective is to optimize donor management and improve access to oocyte donation for recipient patients.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Candidates for egg donation | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of donor candidates undergoing oocyte retrieval
Proportion of patients who underwent oocyte retrieval following ovarian stimulation among all donor candidates who attended a biological consultation for oocyte donation at Nancy University Hospital during the study period.
The outcome will be reported as a percentage (number of oocyte retrieval procedures divided by the total number of donor candidates evaluated).
Measured: From the first biological consultation until oocyte retrieval, assessed up to 12 months
Secondary outcomes (6)
Mean number of oocytes retrieved per oocyte retrieval procedure
Total number of oocytes collected during transvaginal oocyte retrieval divided by the number of retrieval procedures performed.
Measured: At the time of oocyte retrieval procedure, approximately 14-16 days after the start of ovarian stimulation
Mean time from first biological consultation to oocyte retrieval
Mean time interval between the first biological consultation for oocyte donation and the oocyte retrieval procedure among donor candidates who completed ovarian stimulation and underwent oocyte retrieval. The time interval will be calculated in months.
Measured: From the first biological consultation until oocyte retrieval, assessed up to 12 months
Median number of mature oocytes (metaphase II) retrieved per donor
Median number of mature oocytes at the metaphase II stage obtained per oocyte retrieval procedure. Only oocytes classified as metaphase II at the time of assessment in the embryology laboratory will be included in the calculation.
Measured: At the time of oocyte retrieval procedure, approximately 14-16 days after the start of ovarian stimulation
Fertilization rate following in vitro fertilization or intracytoplasmic sperm injection
Proportion of normally fertilized oocytes (two pronuclei) among the total number of inseminated or injected mature oocytes.
Measured: 1 day after fertilization
Clinical pregnancy rate per embryo transfer
Proportion of embryo transfer cycles resulting in a clinical pregnancy defined as the presence of an intrauterine gestational sac with fetal heartbeat detected by ultrasound.
Measured: From embryo transfer until confirmation of clinical pregnancy by ultrasound, assessed up to 8 weeks after embryo transfer
Live birth rate following oocyte donation cycles
Proportion of embryo transfer cycles resulting in at least one live birth.
Measured: From embryo transfer until delivery, assessed up to 41 weeks of gestation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2026
- Study startMar 2026 (estimated)
- Primary completionApr 2026 (estimated)
- Study completionMay 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Egg DonationStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, AIMONE VIANNA Caroline, Central Hospital, Nancy, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07468331
- Sponsor's protocol ID
- 2026PI052
- Acronym
- DONOVO-Nancy
- Status last verified
- Mar 2026
- First submitted
- 2 Mar 2026
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DONOVO-Nancy: Egg Donation at the Assisted Reproductive Technology (ART) Center of the Nancy University Hospital: an Overview of the Donor Journey Since the Revisions to the Bioethics Laws
- ClinicalTrials.gov ID
- NCT07468331
- Acronym / sponsor ID
- DONOVO-Nancy / 2026PI052
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- Mar 2026 (estimated)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- May 2026 (estimated)
- First posted
- 12 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Since the 2021 revision of French bioethics laws, access to assisted reproductive technologies (ART) has expanded, leading to a significant increase in gamete donation requests. In this context, oocyte donation remains a limited resource, with marked disparities between centers and persistent donor shortages.
At the Assisted Reproductive Technology Center of Nancy University Hospital, more than fifty women have initiated an oocyte donation process since the implementation of the new legislation. However, not all candidates complete the donation pathway, and clinical and organizational outcomes have not yet been formally evaluated.
This retrospective observational study will evaluate the oocyte donation pathway at the Assisted Reproductive Technology Center of Nancy University Hospital. The study population will include all women who attended a biological consultation for primary or secondary oocyte donation from the implementation of the new Bioethics laws until December 31, 2025 (study period).
Baseline clinical and biological characteristics of donor candidates will be described, including age, body mass index, anti-Müllerian hormone level, and antral follicle count.
The proportion of donor candidates undergoing oocyte retrieval and the time interval between the first biological consultation and oocyte retrieval will be assessed.
Biological and clinical outcomes will also be analyzed, including the number of oocytes retrieved, the number of mature oocytes (metaphase II) obtained, fertilization rate following in vitro fertilization, clinical pregnancy rate per embryo transfer, and live birth rate.
Results will be compared with national data reported by the French Biomedicine Agency in order to evaluate the activity and outcomes of the center and to identify potential areas for organizational and clinical improvement in the oocyte donation pathway.
The overall objective is to optimize donor management and improve access to oocyte donation for recipient patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Candidates for egg donation | – | – |
Who may qualify
- Ages
- 18 to 38 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- The study population includes all women evaluated for primary or secondary oocyte donation at Nancy University Hospital during the study period. All candidates who attended a biological consultation and initiated the donation assessment process are included, irrespective of donation completion status.
Key inclusion criteria (1 listed)
- All women who attended a biological consultation for primary or secondary oocyte donation at Nancy University Hospital during the study period.
Key exclusion criteria (3 listed)
- Absence of biological consultation for oocyte donation during the study period ;
- Insufficient or missing medical data ;
- Documented opposition to data use for research purposes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportion of donor candidates undergoing oocyte retrieval
Time frame: From the first biological consultation until oocyte retrieval, assessed up to 12 months
Proportion of patients who underwent oocyte retrieval following ovarian stimulation among all donor candidates who attended a biological consultation for oocyte donation at Nancy University Hospital during the study period. The outcome will be reported as a percentage (number of oocyte retrieval procedures divided by the total number of donor candidates evaluated).
6 secondary outcomes
Mean number of oocytes retrieved per oocyte retrieval procedure
Time frame: At the time of oocyte retrieval procedure, approximately 14-16 days after the start of ovarian stimulation
Mean time from first biological consultation to oocyte retrieval
Time frame: From the first biological consultation until oocyte retrieval, assessed up to 12 months
Median number of mature oocytes (metaphase II) retrieved per donor
Time frame: At the time of oocyte retrieval procedure, approximately 14-16 days after the start of ovarian stimulation
Fertilization rate following in vitro fertilization or intracytoplasmic sperm injection
Time frame: 1 day after fertilization
Clinical pregnancy rate per embryo transfer
Time frame: From embryo transfer until confirmation of clinical pregnancy by ultrasound, assessed up to 8 weeks after embryo transfer
Live birth rate following oocyte donation cycles
Time frame: From embryo transfer until delivery, assessed up to 41 weeks of gestation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
Related trials for Egg Donation
Active, not recruitingObservational study
Fresh Versus Vitrified-Warmed Donor Oocytes: Embryological and Clinical Outcomes
Infertility, Donor Oocyte Assisted Reproduction
Recruiting
Validation of Donor Oocytes Semi-automated Vitrification
Vitrification, Egg Donor
RecruitingObservational study
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)
Pre-eclampsia, Oocyte Donation
RecruitingObservational study
Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients
IVF
Not yet recruitingPhase 4
Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial
Adenomyosis of Uterus, Infertility Assisted Reproductive Technology
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Egg Donation and Infertility Assisted Reproductive Technology, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Caroline AIMONE-VIANNA, PHD Medicine (+33631785041, c.aimonevianna@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of donor candidates undergoing oocyte retrieval (time frame: From the first biological consultation until oocyte retrieval, assessed up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.